PDF DatasheetHuman Anti-Involucrin Antibody Product Attributes
Involucrin Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-IVL antibody staining is expected to be primarily localized to the cytosol, centrosome and nuclear bodies. There is variability in either the signal strength or the localization of signal in cytosol from cell to cell.
Observed Antibody Staining Data By Tissue Type:
Variations in Involucrin antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in squamous epithelial cells in the oral mucosa, vagina. More moderate antibody staining intensity was present in squamous epithelial cells in the oral mucosa, vagina. Low, but measureable presence of Involucrin could be seen in. We were unable to detect Involucrin in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Involucrin expression as measured by anti-Involucrin antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | + | – | – | – | ++ |
| IVL Variability | + | + | ++ | + | + | + | ++ | + | ++ | + | + | + | + | + | + | +++ | + | + | + | ++ |
| Involucrin General Information | |
|---|---|
| Alternate Names | |
| Involucrin, IVL | |
| Molecular Weight | |
| 66-170kDa | |
| Chromosomal Location | |
| 1q21.3 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | IVL |
| Entrez Gene ID | 3713 |
| Ensemble Gene ID | ENSG00000163207 |
| RefSeq Protein Accession(s) | NP_005538 |
| RefSeq mRNA Accession(s) | NM_005547 |
| RefSeq Genomic Accession(s) | NC_000001, NG_033018, NC_018912 |
| UniProt ID(s) | P07476 |
| UniGene ID(s) | P07476 |
| HGNC ID(s) | 6187 |
| Cosmic ID(s) | IVL |
| KEGG Gene ID(s) | hsa:3713 |
| PharmGKB ID(s) | PA29985 |
| General Description of Involucrin. | |
| It recognizes a protein of 66kDa-170kDa, identified as involucrin. In Western Blot of cultured human keratinocytes, this MAb reacts with a 120kDa protein. Involucrin is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer. In normal epidermis, it is first expressed in the upper spinous layers,, in keratinocyte cultures, all cells that have left the basal layer express it. Involucrin expression is altered in pathological conditions: in psoriasis, other benign epidermal hyperplasias, involucrin expression begins closer to the basal layer than normal; expression is abnormal in squamous cell carcinomas, premalignant lesions,, is reduced in severe dysplasias of the larynx, cervix. | |
There are no reviews yet.